Altogether, these data indicate that NF-κB and MAPK might be therapeutic targets for IBC specifically and more general for ER− breast tumours as well as for breast tumours with acquired resistance against hormonal therapy. This evidence concerns the gene NFKB1 and breast neoplasm.